Neurotherapeutics

Venom-inspired molecules for the nervous system.

Molecule candidates inspired by neuromodulatory toxins. First target: tremor in Parkinson's disease.

The problem

Four in ten people live with a disease of the nervous system.Source ↗

The nervous system runs on precise signals. Disease scrambles them — and most drugs are too blunt to fix just one.

The consequence

Today's options are blunt or temporary.

Oral drugs

01

General

Hit healthy tissue. The effect fades.

Injections

02

Temporary

Not specific. The relief fades.

Ultrasound

03

Irreversible

Destroys tissue. No way back.

Surgery

04

Last resort

Invasive, and not for everyone.

So the symptoms come back.

The solution

Evolution already solved it.

Over millions of years, venoms evolved to act on the nervous system with a precision no drug has matched. We turn those toxins into therapeutic candidates.

Precise

One target.

Reversible

It lets go.

Tunable

Dial the dose.

A concrete start

We start with tremor in Parkinson's disease.

10M+

people worldwide.Source ↗

≈1M

diagnosed in the United States.Source ↗

$51.9B

cost per year in the United States.Source ↗

The signal from nerve to muscle fires when it shouldn't. A tunable toxin can turn it down.

How it works

Skip ↓

Inspiration

It starts with venom.

Snakes. Spiders. Scorpions.

Challenge 1 · Stability

Hard to make.

We control the disulfide bonds.

The idea

A dimmer, not a switch.

Drag it. It tunes the muscle signal.

45%

Challenge 2 · Effectiveness

How far to turn it down.

Where effectiveness is decided.

Therapeutic window

Specific. Reversible.

Our candidate is designed to act on a precise target and to be adjustable.

Gene therapySpecific. Irreversible.
Our toxin peptide, designed with AISpecific. Reversible.
Focused ultrasoundGeneral. Irreversible.
Oral pills · Deep brain stimulationGeneral. Reversible.

Does this fit your thesis or your pipeline?

We are developing candidates, not offering a treatment.

Talk to the team

Pipeline

One molecule first. A platform behind it.

α-Bungarotoxin LeadAcetylcholine channel · Parkinson's disease
Now: Pre-clinical
Vm24Potassium channel · Multiple sclerosis
Now: Discovery & Formulation
Ts1Sodium channel · Epilepsies
Now: Discovery & Formulation

α-Bungarotoxin is our lead candidate, in pre-clinical validation. Vm24 and Ts1 are in discovery & formulation. Stages are indicative.

Work with us

Two ways in.

Team

Meet our team.

Portrait of Jorge Roldán

JorgeRoldán

CEO

Portrait of Ricardo Miranda

RicardoMiranda, PhD

CSO

Portrait of Samuel Cardoso

SamuelCardoso, PhD

CRO

Portrait of Miguel Ángel Mejía

Miguel ÁngelMejía, PhD

Scientific advisor

Portrait of Víctor Carpanta

VíctorCarpanta, PhD

Scientific advisor

Questions

What you may be asking.

Is this a cure for Parkinson's disease?

No. For now it is a palliative approach aimed at tremor. We are developing candidates, not a treatment.

How would this be different for patients?

Today's options are general, temporary or irreversible. We design a candidate that is specific, reversible and adjustable — aimed at the signal, not the healthy tissue.

Why start with tremor in Parkinson's disease?

When medication stops being enough, the options are few and each has a cost. Tremor in Parkinson's is a large, underserved place to start.

Why venom?

Venoms evolved over millions of years to act on the nervous system with a precision no drug has matched. We turn those toxins into therapeutic candidates.

Isn't it hard to make these molecules?

Yes — stability depends on how their disulfide bonds form. Controlling that is what we know how to do.

What stage are you at?

Preclinical validation. Next: an animal model, co-developed with a biopharma partner.

Is it one molecule or a platform?

One candidate today — α-Bungarotoxin, for Parkinson's. Change the channel and the toxin and the indication changes (Vm24, Ts1).

How would it reach patients?

Preclinical validation, then an animal model with a biopharma, then clinical phases, registration and launch.

Who are you looking to work with?

Investors who want to back one concrete molecule with a platform behind it, and biopharma partners to co-develop the first candidate.

Our vision

Imagine a world where what nature spent millions of years designing can calm disease in the nervous system.

For millions of patients.

Contact

Let's talk.

Investors, biopharma partners and scientists: tell us who you are and what you have in mind. The founding team reads every message.

I'm reaching out about

Prefer email? Write to team@cysbio.techBy sending this message you agree to our Privacy Policy and Terms of Use.